By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Northwest Biotherapeutics, Inc. 

21720 23rd Drive SE, Suite 100

Bothell  Washington  98021  U.S.A.
Phone: 425-608-3000-or-877-606-9246-Toll-Free Fax: 425-608-3026


SEARCH JOBS


Industry
Services


Collaborations

Cytogen Corporation  Development of ex vivo prostate cancer immunotherapy





Company News
Experimental Northwest Biotherapeutics (NWBO) Drug Gets First Slot Under UK Early Access Scheme 9/16/2014 6:00:01 AM
Northwest Biotherapeutics (NWBO) CEO To Present At SMI's 3rd Annual Cancer Vaccines Conference In London 9/15/2014 9:30:39 AM
Northwest Biotherapeutics (NWBO) To Present Updates At Rodman & Renshaw 16th Annual Global Investment Conference 9/8/2014 9:00:16 AM
Northwest Biotherapeutics (NWBO) Completes The Closing Of Its $17.5 Million Convertible Note Offering 8/19/2014 12:57:39 PM
Northwest Biotherapeutics (NWBO) Announces Pricing Of $17.5 Million Offering Of Convertible Notes 8/14/2014 10:47:33 AM
Northwest Biotherapeutics (NWBO) Corrects Ongoing False Claims, Phase 3 Dcvax®-L Trial Is Alive And Well 8/13/2014 7:47:40 AM
Northwest Biotherapeutics (NWBO) Obtains Approvals For Enhancements Of Phase 3 Trial Of Dcvax®-L For Gbm Brain Cancer 8/11/2014 7:46:45 AM
Northwest Biotherapeutics (NWBO) Provides Update About Phase 3 Dcvax®-L Trial For Gbm And "Information Arm" Compassionate Use Patients 8/11/2014 7:45:14 AM
Northwest Biotherapeutics (NWBO) Announces Completion Of DCVax®-Direct Phase I Trial Recruitment 7/16/2014 8:28:38 AM
Northwest Biotherapeutics (NWBO) Biotechnology Industry Organization (BIO) Reaffirms DCVAX®-Direct Clinical Trial Interim Data Announcements 6/20/2014 7:13:51 AM
12345678910...
//-->